← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleLeap Therapeutics, Inc.Phase 1

nivolumab (Opdivo, TRX518 with nivolumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleLeap Therapeutics, Inc.Phase 1

pembrolizumab (Keytruda, TRX518 with pembrolizumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssen Research & Development,…Phase 2

Talacotuzumab (Talacotuzumab)

Myelodysplastic Syndromes · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePreclinical

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleFudan UniversityPhase 2

trastuzumab (Herceptin, Taxanes combined with trastuzumab and pertuzumab.)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
효능 ORR 91.8%임상시험 1상태 RECRUITING
AntibodystaleQamar KhanPhase 2

trastuzumab (Herceptin, Taxotere, Carboplatin, Herceptin + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleImmunocore LtdPhase 3

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

Advanced Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleChinese SLE Treatment And Resea…Approved

Telitacicept (Telitacicept)

ANCA Associated Vasculitis · Systemic Lupus Erythematosus (SLE)

#SystemicLupusErythematosusSLE#Antibody#Approved#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleTianjin Medical University Canc…Phase 2

Tiselizumab (Tiselizumab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

Rectal Cancer; Rectal Cancer Stage II · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab plus Bevacizumab (Tislelizumab plus Bevacizumab)

Astrocytoma of Brain · Astrocytoma of Brain

#AstrocytomaofBrain#Antibody#Phase2#항체#면역항체+2
효능 ORR 37.1%임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Tislelizumab; Bevacizumab · Tislelizumab

#Tislelizumab#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 3

Tislelizumab+Oxaliplatin+Capecitabine (Tislelizumab+Oxaliplatin+Capecitabine)

Gastric Carcinoma · Gastric Carcinoma

#GastricCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 1

trastuzumab (Herceptin, Tislelizumab，atezolizumab or Trastuzumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE

51 / 62 페이지

← 이전다음 →